Table 4.

ORs for smoking modified by the GSTM1 null deletion polymorphism and prostate cancer

Never smokers
Light smokers*
Heavy smokers*
Pint
Cases/controlsOR (95% CI)Cases/controlsOR (95% CI)Cases/controlsOR (95% CI)
Total population
    GSTM1 null74/951.0 (Reference)63/691.18 (0.66-2.09)76/671.56 (0.92-2.66)
    GSTM1 nondeleted86/751.47 (0.85-2.56)51/560.97 (0.55-1.74)78/1030.91 (0.53-1.58)0.03
IOR: 0.56 (0.25-1.26)IOR: 0.40 (0.20-0.80)
Caucasians only
    GSTM1 null68/911.0 (Reference)61/661.28 (0.71-2.31)72/621.73 (0.99-3.05)
    GSTM1 nondeleted72/681.43 (0.81-2.53)46/451.14 (0.60-2.17)71/950.95 (0.53-1.71)0.04
IOR: 0.62 (0.27-1.43)IOR: 0.38 (0.18-0.80)
Low aggressive§
    GSTM1 null36/361.0 (Reference)28/280.84 (0.32-2.20)35/241.44 (0.64-3.25)
    GSTM1 nondeleted34/380.50 (0.21-1.19)18/240.42 (0.16-1.09)30/490.36 (0.15-0.87)0.29
IOR: 1.01 (0.27-3.83)IOR: 0.54 (0.17-1.45)
Low aggressive§ (Caucasians only)
    GSTM1 null34/341.0 (Reference)27/280.74 (0.27-2.02)33/231.35 (0.58-3.16)
    GSTM1 nondeleted28/340.46 (0.19-1.15)18/200.49 (0.18-1.34)26/460.34 (0.13-0.86)0.22
IOR: 1.43 (0.36-5.69)IOR: 0.54 (0.17-1.67)
High aggressive
    GSTM1 null35/541.0 (Reference)32/351.63 (0.75-3.54)37/411.60 (0.74-3.43)
    GSTM1 nondeleted50/313.84 (1.67-8.79)27/271.55 (0.67-3.57)40/471.60 (0.72-3.55)0.03
IOR: 0.25 (0.07-0.83)IOR: 0.26 (0.09-0.75)
High aggressive (Caucasians only)
    GSTM1 null31/531.0 (Reference)31/322.07 (0.92-4.69)36/372.10 (0.92-4.75)
    GSTM1 nondeleted42/284.13 (1.75-9.73)23/202.00 (0.78-5.15)37/431.97 (0.83-4.71)0.02
IOR: 0.23 (0.07-0.82)IOR: 0.23 (0.08-0.70)
  • Abbreviation: IOR, OR for interaction term.

  • * Light smokers are those who smoked ≤20 pack-years and heavy smokers are those who smoked >20 pack-years.

  • P value for test of two interaction terms (GSTM1 × light smokers and GSTM1 × heavy smokers; df = 2).

  • All models are age adjusted.

  • § Includes cases with Gleason score <7 and clinical tumor stage <T2c and their brothers.

  • Includes cases with Gleason score ≥7 or clinical tumor stage ≥T2c and their brothers.